Cyclacel Pharmaceuticals (BGMS) vs. Its Competitors Financial Comparison

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is one of 454 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Cyclacel Pharmaceuticals to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cyclacel Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Cyclacel Pharmaceuticals Competitors	4833	9976	16022	375	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 120.33%. Given Cyclacel Pharmaceuticals’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Cyclacel Pharmaceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares Cyclacel Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%
Cyclacel Pharmaceuticals Competitors	-2,626.20%	-359.54%	-43.35%

Earnings & Valuation

This table compares Cyclacel Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$40,000.00	-$11.21 million	-0.02
Cyclacel Pharmaceuticals Competitors	$435.56 million	-$68.47 million	-10.32

Cyclacel Pharmaceuticals’ competitors have higher revenue, but lower earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Cyclacel Pharmaceuticals has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals’ competitors have a beta of 11.28, suggesting that their average share price is 1,028% more volatile than the S&P 500.

Insider & Institutional Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 39.3% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Cyclacel Pharmaceuticals competitors beat Cyclacel Pharmaceuticals on 8 of the 13 factors compared.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.